Specialty Pharmacy

Pharmacy Times® interviewed Tim Safley and Jon Pritchett of ACHC on evaluating the opportunities for long-term care (LTC) pharmacies in relation to specialty pharmacy accreditation.

A potential correlation between processed food and breast cancer has been discovered.

Multiple pharmacies recently received letters from ESI stating that on behalf of TRICARE and the Defense Health Agency, ESI was recouping money for compound drug claims submitted in 2015.

According to a recent study published in Gut, inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn disease, is associated with a more than doubled likelihood of developing dementia.

Urothelial carcinoma accounts for approximately 90% of all bladder cancers and becomes increasingly challenging to treat as it spreads through the layers of the bladder wall.

The development and use of specialty pharmaceuticals have significantly affected global health care practices and costs.

According to a press release, this is the first single-agent, anti-PD-1 therapy approved in the first-line environment for this patient population.

Pharmacy Times® interviewed Cory Kidd, PhD, CEO and founder of Catalia Health, on the value of technology in innovating patient care in the field of specialty pharmacy.

Erlotinib taken with gemcitabine was approved by the FDA for locally advanced, inoperable, or metastatic pancreatic cancer in 2005.

A new study found disturbing evidence that black cancer survivors are more likely to face financial hardship on high deductible health plans than their white counterparts.

Organ transplants from seropositive donors carry a high risk of infection from the transplanted organ.

Dravet syndrome is a life-threatening, rare, and chronic form of epilepsy and is often characterized by severe, unrelenting seizures despite medical treatment, according to the FDA press release.

The pharmaceutical industry is already seeing the immense benefit of AI and machine-learning technology.

Many companies are working with health systems to transition patients from the hospital to in-home care as quickly as possible.

Pharmacy Times spoke with Ali McBride, PharmD, MS, BCOP, FASHP, FAzPA, about how the drug niraparib could affect treatment options for patients with ovarian cancer.

Pembrolizumab has been approved by the FDA as a monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma.

According to the survey results, not only do a majority of the 500 respondents experience fear of bleeding events, but many of them also avoid or modify activities in order to mitigate their risk.

A recent qualitative study presented a potential explanation for why health system specialty pharmacies often find it difficult to partner with payers.

Cognitive impairment is extremely common among patients with MS, affecting approximately two-thirds of this patient population.

Pharmacists, being the most accessible health care professionals, have an important role to play in the management of this pandemic.

Molecule binds and blocks a previously unknown opioid receptor in the brain, potentially revolutionizing pain, depression, and cancer treatment.

The objective of the study was to examine a large clinical dataset of LGSC through the Ovarian Cancer Association Consortium, with the primary goal of identifying factors that affect survival.

Women diagnosed with breast cancer while breastfeeding may receive treatments that decrease milk production or are contraindicated.

After up to 4.8 years of treatment with nusinersen, 100% of children with spinal muscular atrophy (SMA) who were treated pre-symptomatically are still alive.

A study presented at the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer showed menstrual cups may provide a novel, less invasive, and more comfortable approach to the diagnosis of endometrial cancer.

Oncology drugs have especially fallen victim to chronic shortages, consequently affecting the availability of substitute agents.

The researchers identified 87 articles using the PubMed and PsycINFO databases and the 2017 American Academy of Neurology (AAN) criteria for therapeutic trials.

With new and varying options for maintenance therapy in patients with ovarian cancer, patients may express a preference when discussing potential maintenance treatments and their adverse effects.

Researchers found that replacing 30 minutes of inactivity with exercise significantly reduces the risk of cancer-related death.

Tumor- induced osteomalacia is a rare disease that is characterized by tumors causing soft and weakened bones.